Patel Ashish D, Connors Alexa, Esch Megan E
Department of Neurology, Geisinger Health System, Danville, PA, USA.
Mult Scler. 2025 Feb;31(2):242-245. doi: 10.1177/13524585241303479. Epub 2024 Dec 7.
Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab.
To report the first case of ofatumumab-associated colitis in MS and discuss its implications.
Case report.
A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation.
This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.
